@article{5d327702102949428a3d11f6c6a1ed41,
title = "Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer",
abstract = "Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin's lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic colorectal cancer patients whose tumor harbors deficient mismatch repair, or microsatellite-instability high and have progressed on conventional chemotherapy. In this review, we will discuss the use, efficacy, and safety of this agent in microsatellite-instability high metastatic colorectal cancer.",
keywords = "MSI-H, PD-1, colorectal, immunotherapy, microsatellite instability, nivolumab",
author = "Sarshekeh, {Amir Mehrvarz} and Overman, {Michael J.} and Scott Kopetz",
note = "Funding Information: S Kopetz and M Overman have received funding for advisory boards from BMS and Merck. The work discussed in the above manuscript arose, in whole or in part, from direct costs funded by NIH, or from NIH staff, grant number: NIH ROI CA187238. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2018 2018 Future Medicine Ltd.",
year = "2018",
month = aug,
doi = "10.2217/fon-2017-0696",
language = "English (US)",
volume = "14",
pages = "1869--1874",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "18",
}